Dendritic cell-based immunotherapy

doi:10.1038/CR.2016.157

Open AccessJournal ArticleDOI

Dendritic cell-based immunotherapy

Rachel Lubong Sabado, +2 more

- 01 Jan 2017 -

Cell Research

- Vol. 27, Iss: 1, pp 74-95

TLDR

What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.

Abstract:

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.

Citations

PDF

Open Access

More filters

Journal ArticleDOI

Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Daniel Christoph Amberger, +1 more

- 05 Nov 2020 -

Transfusion Medicine and Hemotherapy

TL;DR: DC/DCleu-based therapies seem to be promising treatment tools for patients with AML or MDS but ongoing research including trials in animals and humans have to be performed.

...read moreread less

Journal ArticleDOI

Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells.

Yanan Wang, +15 more

- 01 Dec 2020 -

Cell Death and Disease

TL;DR: It is established that EZH2 exhibits anti-inflammatory effects through inhibition of RUNX1 to regulate DC functions and that inhibition of EZh2 alleviates P. acnes plus LPS-induced FHF, probably by inhibiting DC-induced adaptive immune responses.

...read moreread less

Book ChapterDOI

Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses.

Shentong Fang, +3 more

- 01 Jan 2020 -

Methods in Enzymology

TL;DR: A systematic methodology is presented that exploits the murine ear pinna model to study differential immune cell recruitment by dead/dying cancer cells injected in vivo, thereby modeling the site-of-injection relevant for anticancer vaccines.

...read moreread less

Journal ArticleDOI

DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy.

Lele Sun, +9 more

- 19 Apr 2022 -

Journal of the American Chemical Society

TL;DR: This work provides a new design of aAPCs for in vivo applications in tumor immunotherapy, and the lipid-DNA-mediated noninvasive live cell surface engineering would be a powerful tool for designing cell-based therapeutics.

...read moreread less

Journal ArticleDOI

A new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model

Nahla E. El-Ashmawy, +4 more

- 01 Jul 2019 -

Molecular Immunology

TL;DR: Vaccination with CSC loaded DCs significantly reduced tumor size, prolonged survival rate, increased IFN-γ serum levels, and upregulated p53gene expression in SEC bearing mice, opening the field for combining CSC-targeted immunotherapy with repeated low doses chemotherapy as an effective strategy to improve anticancer immune responses.

...read moreread less

Collapse

References

PDF

Open Access

More filters

Journal ArticleDOI

Toll-like receptor signalling

Shizuo Akira, +1 more

- 01 Jul 2004 -

Nature Reviews Immunology

TL;DR: Rapid progress that has recently improved the understanding of the molecular mechanisms that mediate TLR signalling is reviewed.

...read moreread less

Journal ArticleDOI

Immunobiology of Dendritic Cells

Jacques Banchereau, +7 more

- 01 Jan 2000 -

Annual Review of Immunology

TL;DR: Dendritic cells are antigen-presenting cells with a unique ability to induce primary immune responses and may be important for the induction of immunological tolerance, as well as for the regulation of the type of T cell-mediated immune response.

...read moreread less

Journal ArticleDOI

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, +28 more

- 03 Apr 2015 -

Science

TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.

...read moreread less

Journal ArticleDOI

Neoantigens in cancer immunotherapy

Ton N. Schumacher, +1 more

- 03 Apr 2015 -

Science

TL;DR: Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.

...read moreread less